How to Get Vyleesi (Bremelanotide) in New Mexico

What Vyleesi Is and Why It Requires a Prescription

Bremelanotide, sold as Vyleesi, is the only FDA-approved melanocortin receptor agonist for HSDD in premenopausal women. The FDA granted approval on June 21, 2019, based on the RECONNECT trial program. Hypoactive sexual desire disorder is defined as persistently low sexual desire that causes marked distress, and it affects an estimated 10% of premenopausal women in the United States. [1]

Bremelanotide is a prescription-only Schedule-unscheduled melanocortin agonist. It requires a clinician evaluation because transient blood pressure elevation occurs in roughly 40% of doses, according to the FDA prescribing label. [2] That cardiovascular screen is not optional. A prescriber must confirm no uncontrolled hypertension, no history of cardiovascular disease, and no concurrent use of naltrexone before issuing the script.

How Bremelanotide Works

Bremelanotide activates MC1R, MC3R, MC4R, and MC5R receptors centrally, boosting dopaminergic and reducing serotonergic signaling in the hypothalamus. This is a different mechanism from flibanserin (Addyi), which is a serotonin receptor modulator. The central action means the drug does not require sexual stimulation to work and produces desire rather than arousal, a distinction that matters when counseling patients. [3]

RECONNECT Trial Results

The RECONNECT trials (two phase-3 randomized controlled trials, N=1,267 combined) showed that women using bremelanotide reported a statistically significant increase in satisfying sexual events and a reduction in distress compared to placebo at 24 weeks. [1] Specifically, the desire domain of the Female Sexual Function Index (FSFI-d) score improved by a mean of 0.5 points over placebo (P<0.001). Nausea was the most common adverse effect, occurring in 40.4% of bremelanotide-treated subjects versus 1.4% placebo. [1]

New Mexico Prescribing Rules: Who Can Write the Script

In New Mexico, the prescribing field for bremelanotide is relatively open. Licensed MDs, DOs, nurse practitioners (NPs), and physician assistants (PAs) can all legally prescribe Vyleesi, provided they are acting within their scope of practice and have conducted an appropriate clinical evaluation. [4]

Nurse Practitioners and Full Practice Authority

New Mexico grants NPs full practice authority, meaning an NP does not need a collaborating physician to prescribe Vyleesi. This makes NP-led telehealth platforms a practical and legally sound option for New Mexico residents. The New Mexico Nursing Practice Act (NMSA 1978, § 61-3-23.2) codifies this authority. [4]

Physician Assistants in New Mexico

PAs in New Mexico practice under a supervision agreement but may prescribe Schedule II, V controlled substances and all non-scheduled drugs, including bremelanotide. Patients using a PA-staffed telehealth service should confirm the supervising physician has agreed to cover reproductive and sexual health prescribing in the collaboration agreement, but this is a routine administrative check rather than a clinical barrier.

Specialist vs. Primary Care Prescribing

No guideline restricts Vyleesi to gynecologists or sexual medicine specialists. A primary care physician or a certified nurse-midwife can prescribe it. The Endocrine Society and the International Society for the Study of Women's Sexual Health (ISSWSH) both note that HSDD diagnosis requires excluding comorbid depression, relationship distress, and medication-induced desire changes before treatment. [5] A thoughtful primary care visit that covers those domains is clinically sufficient.

Telehealth Options for Getting Vyleesi in New Mexico

New Mexico law permits telehealth prescribing of non-controlled medications, and bremelanotide is not a controlled substance. That means a fully remote consultation via video, phone, or asynchronous questionnaire can legally result in a valid New Mexico prescription. [6]

What a Telehealth Visit Covers

A standard telehealth intake for Vyleesi typically runs 20 to 40 minutes and covers:

• Confirmation of HSDD diagnosis (low desire causing distress, not explained by relationship conflict or medication side effects)
• Blood pressure reading (patient self-reported or from a recent clinic visit, documented in chart)
• Cardiovascular history review
• Current medication reconciliation, specifically screening for naltrexone or other opioid antagonists, which are contraindicated
• Reproductive status confirmation (premenopausal; bremelanotide is not FDA-approved for postmenopausal women)

Blood pressure monitoring is the single most safety-relevant step. The FDA label notes that mean maximum systolic BP increase is 6 mmHg and mean maximum diastolic increase is 3 mmHg, occurring approximately 4 hours post-dose. [2] Patients with baseline BP above 130/85 mmHg should have that addressed before starting therapy.

Asynchronous vs. Synchronous Telehealth

Some telehealth platforms offer asynchronous (questionnaire-only) prescribing for Vyleesi. New Mexico does not prohibit asynchronous prescribing for non-controlled drugs, but the clinician signing the prescription remains responsible for clinical appropriateness. HealthRX uses synchronous video visits for all first-time Vyleesi prescriptions to allow real-time blood pressure review and patient education on injection technique.

Turnaround Time

Most telehealth platforms send the prescription electronically the same day as the consult if the clinical criteria are met. Shipping from a specialty or mail-order pharmacy to a New Mexico address typically adds three to five business days. Total time from booking a consult to receiving the auto-injector at home is generally seven to fourteen days. [6]

Pharmacies in New Mexico That Dispense Vyleesi

Retail and Specialty Pharmacy Options

Brand-name Vyleesi (Palatin Technologies / AMAG Pharmaceuticals) is dispensed through specialty pharmacies. Not every corner retail pharmacy stocks it. Patients should call ahead or request that their prescriber send the script to a specialty pharmacy with confirmed inventory.

Major pharmacy benefits managers (PBMs) that cover Vyleesi on formulary can process a mail-order fill. The brand list price is approximately $1,000 per auto-injector, but manufacturer copay assistance can reduce out-of-pocket cost to as low as $99 per month for commercially insured patients who qualify. [2]

503A Compounding Pharmacies in New Mexico

New Mexico state law permits 503A compounding pharmacies to compound patient-specific formulations, including bremelanotide, when a licensed prescriber provides a valid patient-specific prescription and documents a clinical rationale. [7] Compounded bremelanotide is not FDA-approved, but 503A compounding is legal and regulated by the New Mexico Board of Pharmacy. Compounded versions may lower cost substantially relative to brand Vyleesi.

Patients considering compounded bremelanotide should ask their pharmacy to confirm:

• PCAB accreditation or equivalent quality certification
• Certificate of analysis (CoA) from a third-party lab for each batch
• Sterile compounding license (required because bremelanotide is a subcutaneous injection)

Transferring a Prescription to New Mexico

If you have an existing Vyleesi prescription from another state, a licensed New Mexico pharmacy can fill it as long as the prescribing clinician holds an active license in the state where they evaluated you. Bremelanotide is not a controlled substance, so no DEA-registration transfer is required. The prescription is valid as written. Confirm your original prescriber is still reachable for refill authorization, because most pharmacies require that contact before dispensing subsequent fills.

Insurance and Prior Authorization in New Mexico

Commercial Insurance

Most commercial plans in New Mexico classify Vyleesi as a Tier 3 or Tier 4 specialty drug. Prior authorization (PA) is the norm. A typical PA dossier for bremelanotide in New Mexico requires:

• ICD-10 code F52.0 (hypoactive sexual desire dysfunction) documented in the chart
• Documentation that the patient is premenopausal
• Attestation that HSDD is causing marked personal distress (FSFI-d score <3.3 is commonly cited in PA submissions)
• Absence of contraindications (uncontrolled hypertension, cardiovascular disease, naltrexone use)
• In some plans: documentation that lifestyle counseling or sex therapy was offered or attempted

The FDA prescribing label is the foundational document prescribers attach to PA appeals. [2]

New Mexico Medicaid

New Mexico Medicaid (Centennial Care) does not cover Vyleesi. Patients on Medicaid should discuss the manufacturer savings card, 503A compounding options, or a peer-reviewed clinical rationale for any plan exception request. No state carve-out or waiver program currently covers bremelanotide for Medicaid beneficiaries in New Mexico as of the date of this article.

Appeals Process

If a PA is denied, New Mexico state law (NMSA 1978, § 59A-57) requires insurers to provide a written denial with the clinical criteria used. Prescribers can file a peer-to-peer review within 30 days. Published data from RECONNECT and the ISSWSH clinical practice guideline citing bremelanotide as a first-line agent for HSDD strengthen appeal letters significantly. [1][5]

What to Expect at Your First Dose

Injection Technique

Vyleesi comes as a pre-filled, single-use auto-injector containing 1.75 mg bremelanotide in 0.4 mL. Inject subcutaneously into the abdomen or thigh 45 minutes before anticipated sexual activity. Avoid the upper arm (higher rate of injection-site bruising in clinical trials). Do not use more than one dose per 24 hours. [2]

Managing Nausea

Nausea is the most common side effect, affecting about 40% of users in RECONNECT. [1] Taking an over-the-counter antiemetic such as ondansetron 4 mg orally 30 minutes before injection reduces nausea incidence substantially in clinical practice, though this combination is not formally studied in a published RCT as of this writing. Eating a light meal before injecting also reduces nausea severity based on patient-reported data in the RECONNECT open-label extension. [1]

Flushing and Blood Pressure

Flushing occurs in approximately 20% of doses. [2] The transient BP rise peaks around 4 hours post-injection. Patients should avoid vigorous exercise and should not drive if they feel lightheaded. Most transient hemodynamic changes resolve within 12 hours. A home blood pressure cuff for the first two doses is a practical safety measure.

HealthRX Dosing Readiness Framework

Before a New Mexico patient self-administers their first Vyleesi dose, our clinical team uses the following four-point readiness check:

1. Resting BP documented at <130/85 mmHg within the prior 30 days
2. No naltrexone, opioid analgesic, or opioid agonist therapy active in medication list
3. Patient demonstrates correct auto-injector technique via video or in-person
4. Antiemetic strategy discussed and patient has antiemetic on hand if desired

Patients who do not clear all four points receive a follow-up consult before their prescription is transmitted.

Monitoring and Follow-Up After Starting Vyleesi

The FDA label does not mandate a specific monitoring schedule after the first prescription. [2] HealthRX recommends a 30-day check-in to assess:

• Frequency of use (clinical benefit is assessed over at least 8 weeks of as-needed use)
• Nausea severity and whether the antiemetic strategy is working
• Blood pressure stability
• Patient satisfaction using a validated tool such as the Female Sexual Distress Scale-Revised (FSDS-R)

The RECONNECT trials used 24-week endpoints, meaning patients and clinicians should give the drug a fair trial before concluding it is not effective. [1] One or two uses in the first month is not an adequate trial. A realistic assessment requires 8 to 12 weeks and at least 4 to 6 uses.

Combining Vyleesi With Other HSDD Treatments

Flibanserin (Addyi) and bremelanotide are the only two FDA-approved drugs for HSDD in premenopausal women. [2][8] They should not be combined. Flibanserin has a serious interaction with alcohol and CYP3A4 inhibitors; bremelanotide does not share these interactions but is pharmacologically distinct. Some women who do not respond to flibanserin are switched to bremelanotide, and vice versa. This is a clinically reasonable approach supported by the ISSWSH 2019 consensus. [5]

Pelvic floor physical therapy and cognitive behavioral sex therapy are evidence-based non-pharmacologic treatments that can be used alongside bremelanotide. [9] New Mexico has licensed pelvic floor PTs in Albuquerque, Santa Fe, and Las Cruces, and several telehealth sex therapy platforms serve New Mexico residents. Combining pharmacotherapy with psychosexual counseling produces better distress reduction scores than either alone in observational data. [9]

Testosterone therapy is sometimes used off-label for HSDD in premenopausal women. The Endocrine Society's 2019 guideline states evidence is insufficient to recommend testosterone for premenopausal HSDD outside of surgically induced menopause, which distinguishes it clearly from bremelanotide's approved status. [5]

Frequently Asked Questions